Company Profile
ANTENGENE-B
Description
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, Hong Kong, Macau, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR kinase inhibitor for the treatment of cervical cancer and other advanced solid tumors. The company also develops other clinical stage assets, such as ATG-016, a second generation XPO1 inhibitor, which is in Phase II open-label study in patients with patients with high-risk myelodysplastic syndromes; ATG-017, an ERK1/2 inhibitor for the treatment of advanced/metastatic solid tumors and hematologic malignancies; ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma; ATG-037, an CD73 inhibitor for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; and ATG-031 an anti-CD24 monoclonal antibody. In addition, its pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor and ATG102, an LILRB4 x CD3 T cell engager. Further, it develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.
Reports
This company has 1 ESG reports available.
ESG Performance Overview
Select a KPI indicator to view performance trend
KPI Indicators
A1.1 Emission Types and Data
3 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| SOₓ Emissions | 1 | |
| NOₓ Emissions | 1 | |
| Airborne Particulate Matter (PM) Emissions | 1 |
A1.2 Direct (Scope 1) and Indirect (Scope 2) GHG Emissions
5 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Total GHG Emissions Intensity (By Employee) | 1 | |
| Total GHG Emissions Intensity (By Area) | 1 | |
| Total GHG Emissions | 1 | |
| Direct GHG Emissions (Scope 1) | 1 | |
| Indirect Energy Emissions (Scope 2) | 1 |
A1.3 Hazardous Waste
4 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Hazardous Waste Recycled | 1 | |
| Hazardous Waste (Electronic and IT Equipment) | 1 | |
| Hazardous Waste (Used Batteries) | 1 | |
| Total Hazardous Waste | 1 |
A1.4 Non-Hazardous Waste
2 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Non-Hazardous Waste Recycled | 1 | |
| Total Non-Hazardous Waste Intensity (By Employee) | 1 |
A2.1 Energy Consumption
6 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Total Electricity Consumption Intensity (By Employee) | 1 | |
| Total Electricity Consumption Intensity (By Area) | 1 | |
| Gasoline Consumption | 1 | |
| Total Indirect Energy Consumption | 1 | |
| Purchased Electricity | 1 | |
| Grid Electricity Consumption | 1 |
A2.2 Water Consumption
2 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Water Consumption | 1 | |
| Water Consumption Intensity (By Revenue) | 1 |
B1.1 Amount and Distribution of Workforce
21 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Number of Total Employees | 1 | |
| Number of Male Employees | 1 | |
| Number of Female Employees | 1 | |
| Percentage of Male Employees | 1 | |
| Percentage of Female Employees | 1 | |
| Number of Full-time Employees | 1 | |
| Percentage of Full-time Employees | 1 | |
| Number of Employees Aged Below 30 | 1 | |
| Number of Employees Aged 30-50 | 1 | |
| Number of Employees Aged Above 50 | 1 | |
| Percentage of Employees Aged Below 30 | 1 | |
| Percentage of Employees Aged 30-50 | 1 | |
| Percentage of Employees Aged Above 50 | 1 | |
| Number of Employees in East China | 1 | |
| Number of Employees in Central China | 1 | |
| Number of Employees in North China | 1 | |
| Number of Employees in South China | 1 | |
| Percentage of Employees in East China | 1 | |
| Percentage of Employees in Central China | 1 | |
| Percentage of Employees in North China | 1 | |
| Percentage of Employees in South China | 1 |
B1.2 Employee Turnover Rate
9 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Turnover Rate of Female Employees | 1 | |
| Turnover Rate of Male Employees | 1 | |
| Turnover Rate of Employees Aged Below 30 | 1 | |
| Turnover Rate of Employees Aged 30-50 | 1 | |
| Turnover Rate of Employees Aged Above 50 | 1 | |
| Turnover Rate of Employees in East China | 1 | |
| Turnover Rate of Employees in Central China | 1 | |
| Turnover Rate of Employees in North China | 1 | |
| Turnover Rate of Employees in South China | 1 |
B2.1 Number and Rate of Work-related Fatalities
1 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Number of Work-related Fatalities | 1 |
B2.2 Lost Days Due to Work Injury
1 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Lost Days Due to Work-related Injuries | 1 |
B3.1 The Percentage of Employees Trained
3 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Percentage of Trained Male Employees | 1 | |
| Percentage of Trained Female Employees | 1 | |
| Percentage of Trained Senior Management | 1 |
ESG Reports
| Year | Report Title | Publication Date | Raw KPIs | Standard KPIs | Processed | Actions |
|---|---|---|---|---|---|---|
| 2020 | 2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 2021-07-19 | 55 | 57 | Yes |